ZNF554

ZNF554 is a KRAB-domain zinc finger transcription factor that functions as a transcriptional regulator of trophoblast invasion and as a tumor suppressor in multiple cancer contexts. In placental trophoblast cells, ZNF554 activates the NRF2 antioxidant pathway via the p62-Keap1-Nrf2 axis, and its loss elevates reactive oxygen species, promotes apoptosis and autophagy, and impairs cell migration and invasion; epigenetic silencing of ZNF554 by promoter DNA hypermethylation is associated with preterm preeclampsia (PMID:30135684, PMID:37804692). In cancer cells, ZNF554 directly activates RBM5 transcription to inactivate WNT/β-catenin signaling and suppresses the PI3K-Akt pathway, leading to cell cycle arrest and reduced proliferation, migration, and invasion (PMID:32796700, PMID:38619681).

1. 2018 Medium

   Establishing that ZNF554 is epigenetically regulated in the placenta answered the question of why trophoblast invasion is impaired in preeclampsia: promoter DNA hypermethylation silences ZNF554, identifying it as a hub transcription factor in placental gene networks.

   Evidence Integrated placental transcriptomics, DNA methylation profiling, and trophoblast cell experiments

   PMID:30135684

   Open questions at the time

   • Direct transcriptional targets of ZNF554 in trophoblasts were not identified
   • Causal relationship between ZNF554 silencing and preeclampsia not tested in vivo
   • Mechanism by which ZNF554 promotes trophoblast invasion was not delineated
2. 2020 Medium

   Demonstrating that ZNF554 overexpression arrests cell cycle and suppresses PI3K-Akt signaling in glioblastoma cells established its capacity to function as a tumor suppressor transcription factor beyond the placenta.

   Evidence Transient overexpression in U87 glioblastoma cells with genome-wide transcriptomics, proliferation, and cell cycle assays

   PMID:32796700

   Open questions at the time

   • No direct target genes were validated by ChIP or reporter assays
   • Tumor suppressor activity not confirmed in vivo or in patient-derived models
   • Mechanism of PI3K-Akt suppression (direct vs. indirect) was unresolved
3. 2023 Medium

   Defining the NRF2 antioxidant axis as a downstream effector of ZNF554 in trophoblasts resolved how ZNF554 loss leads to oxidative stress, apoptosis, autophagy, and impaired invasion — linking its silencing mechanistically to placental dysfunction.

   Evidence siRNA knockdown and overexpression in HTR8/SVneo and JEG3 trophoblast lines; ROS, apoptosis, autophagy marker, and migration/invasion assays with NAC rescue

   PMID:37804692

   Open questions at the time

   • Whether ZNF554 directly binds NRF2 pathway gene promoters was not tested
   • In vivo relevance in placental tissue or animal models not demonstrated
   • Relative contribution of apoptosis versus impaired migration to invasion defect unclear
4. 2024 Medium

   Identifying RBM5 as a direct transcriptional target of ZNF554 and showing that the ZNF554–RBM5–WNT/β-catenin axis suppresses endometrial cancer provided the first ChIP-validated target gene and a defined epistatic pathway for ZNF554's tumor suppressor activity.

   Evidence ChIP and luciferase reporter assays confirming direct RBM5 activation; lentiviral overexpression/knockdown with RBM5 rescue; western blot for β-catenin and p-GSK-3β in endometrial cancer cells

   PMID:38619681

   Open questions at the time

   • Genome-wide binding profile of ZNF554 has not been determined
   • Whether the ZNF554–RBM5 axis operates in trophoblast or glioma contexts is unknown
   • In vivo tumor suppression by ZNF554 has not been demonstrated

• The genome-wide direct target repertoire of ZNF554, its in vivo roles in placentation and tumorigenesis, and how its KRAB domain contributes to transcriptional activation versus repression remain unresolved.
• No ChIP-seq or CUT&RUN data to define the full cistrome
• No animal model (knockout or conditional) for ZNF554
• Mechanism by which a KRAB-ZNF activates (rather than represses) transcription is unexplained